IO-202
IO-202 is a high-affinity LILRB4/ILT3 binder and myeloid checkpoint inhibitor. IO-202 blocks APOE binding and LILRB4 activation to reverse T-cell suppression and enhance T-cell cytotoxicity, while eliminating LILRB4-high-expressing leukemic blasts via ADCC and ADCP mechanisms. IO-202 promotes dendritic cell maturation and antigen presentation, reshapes the phenotype of tumor-associated macrophages, and reduces myeloid-derived suppressor cells. IO-202 is widely applicable to research on relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
LILRB4 |
In Vitro
IO-202 reverses AML cell-mediated T-cell suppression and activates T-cell cytotoxicity against leukemic cells in vitro via high-affinity binding to human LILRB4 and blockade of APOE-mediated LILRB4 activation[1].
IO-202 (15 μg/mL; 2 days) enhances DC activation (increased CD86 and HLA-DR expression) and reduces a tolerogenic phenotype (decreased CD209 expression) when used to treat healthy human donor monocyte-derived dendritic cells during LPS stimulation[3].
IO-202 (15 μg/mL; 2 days during Mo-DC culture, 4 days during T cell co-culture) enhances DC activation marker expression, IL-12 production, and T cell-derived IFNγ production when used to treat human monocyte-derived dendritic cells during CD40L-induced maturation/activation and subsequent allogeneic T cell co-culture, but has no effect on immature Mo-DCs[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human monocyte-derived dendritic cells
-
Concentration:15 μg/mL
-
Incubation Time:2 days during Mo-DC culture, 4 days during T cell co-culture
-
Result:Enhanced DC activation marker expression, IL-12 production, and T cell-derived IFNγ production.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cx3cr1-Cre/Rosa26-LILRB4 transgenic[3]
-
Dosage:10 mg/kg
-
Administration:administered on day 10 and day 20 post tumor implant
-
Result:Achieved significant tumor growth inhibition with mean tumor volume at day 27 post tumor implant being substantially lower.
Reduced the frequencies of myeloid-derived suppressor cells (including PMN-MDSCs) among tumor-infiltrating leukocytes.
Increased the frequencies of conventional CD4+ T cells and NKT cells among tumor-infiltrating leukocytes.
Decreased the expression of the anti-inflammatory marker CD206 on tumor-associated macrophages (TAMs).
Increased MHCII expression on TAMs.
Gene ID
Accession
Target
LILRB4/ILT3/CD85k
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)